Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis-Reference-Cited by-同舟云学术

Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis

Published:2012-07-05 Issue:6 Volume:18 Page:881-887
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Martinowitz U.¹,Shapiro A.²,Quon D. V.³,Escobar M.⁴,Kempton C.⁵,Collins P. W.⁶,Chowdary P.⁷,Makris M.⁸,Mannucci P. M.⁹,Morfini M.¹⁰,Valentino L. A.¹¹,Gomperts E.¹²,Lee M.¹²

Affiliation:

1. Institute of Thrombosis and Hemostasis and the National Hemophilia Center; Sheba Medical Center; Tel Hashomer; Israel

2. Indiana Hemophilia and Thrombosis Center; Indianapolis; IN; USA

3. The Hemophilia Treatment Center at Los Angeles Orthopaedic Hospital; Los Angeles; CA; USA

4. University of Texas Houston Health Sciences Center; Houston; TX; USA

5. Aflac Cancer Center and Blood Disorders Service; Emory University School of Medicine; Atlanta; GA; USA

6. Arthur Bloom Haemophilia Centre; University Hospital of Wales School of Medicine; Cardiff University; Cardiff; UK

7. KD Haemophilia Centre and Thrombosis Unit; Royal Free Hospital; London; UK

8. Sheffield Haemophilia and Thrombosis Centre; Royal Hallamshire Hospital; Sheffield; UK

9. Scientific Direction and A. Bianchi Bonomi Hemophilia and Thrombosis Center; IRCCS Cà Granda Foundation Maggiore Policlinico Hospital; Milan; Italy

10. Agency for Haemophilia; Azienda Ospedaliero-Universitaria Careggi; Florence; Italy

11. Rush Hemophilia and Thrombophilia Center; Rush University Medical Center; Chicago; IL; USA

12. Inspiration Biopharmaceuticals; Cambridge; MA; USA

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2012.02897.x/fullpdf

Reference16 articles.

1. Pharmacovigilence studies in haemophilia;Ingerslev;Haemophilia,2007

2. National Hemophilia Foundation Hemophilia B (Factor IX) http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=181&contentid=46&rptname=bleeding

3. Haemophilias A and B;Bolton-Maggs;Lancet,2003

4. Hemophilia B: Christmas disease;Giangrande;Expert Opin in Pharmacother,2005

5. Haemophilia B: impact on patients and economic burden of disease;Gater;Thromb Haemost,2011

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revised terminal half‐life of nonacog alfa as derived from extended sampling data: A real‐world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis;Haemophilia;2022-04-14

2. Characterisation of recombinant factor IX before and after GlycoPEGylation;International Journal of Pharmaceutics;2020-10

3. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review;Research and Practice in Thrombosis and Haemostasis;2019-05-20

4. Advances and innovations in haemophilia treatment;Nature Reviews Drug Discovery;2018-06-08

5. Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia;Therapeutic Advances in Hematology;2018-06